Annotation Detail
Information
- Associated Genes
- EGFR
- Associated Variants
-
EGFR MUTATION
EGFR MUTATION - Associated Disease
- lung adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy. It was found that EGFR Mutant status was a significant positive prognostic factor for overall survival. (HR, 0.33; 95% CI, 0.19 to 0.59; P<0.01)
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/3792
- Gene URL
- https://civic.genome.wustl.edu/links/genes/19
- Variant URL
- https://civic.genome.wustl.edu/links/variants/442
- Rating
- 3
- Evidence Type
- Prognostic
- Disease
- Lung Adenocarcinoma
- Evidence Direction
- Supports
- Evidence Level
- B
- Clinical Significance
- Better Outcome
- Pubmed
- 21969500
Drugs